Affinity Biosensors

What Affinity Biosensors does

Affinity Biosensors, LLC is a Santa Barbara, California-based medical device company founded in 2006 that develops and manufactures the LifeScale AST system, a rapid phenotypic antimicrobial susceptibility testing (AST) platform for hospital clinical microbiology laboratories. The system uses patented microfluidic sensor technology to measure individual bacterial cell mass at femtogram levels, generating population profiles that a proprietary AI-Predictor analyzes to produce Minimum Inhibitory Concentration (MIC) results in approximately 4.5 hours directly from positive blood cultures, compared with 16–24 hours for conventional AST methods. The platform has received three sequential FDA clearances (initial in April 2024, a second in 2024, and a third in October 2025 expanding to less-prevalent organisms), FDA Breakthrough Device Designation for the LifeScale Yeast Kit (LSYST) covering antifungal AST including Candida auris, and ISO 13485:2016 certification through the Medical Device Single Audit Program (MDSAP) covering the US, Canada, Australia, Brazil, and Japan.

The company's commercial offering consists of the LifeScale AST benchtop instrument plus proprietary consumable kits (the LSGN Gram-negative kit and the LSYST yeast kit), following a capital equipment plus recurring consumables model typical of clinical diagnostics. Affinity Biosensors sells directly to US hospital clinical laboratories through an enterprise field-sales motion, supported by scientific publications (including a peer-reviewed article in the Journal of Clinical Microbiology), industry conference presence (SCACM, ASM, ECCMID), and clinical validation evidence across 10 US hospital sites demonstrating 95.4% essential agreement and 94.8% categorical agreement with standard of care. The company is led by CEO Dr. Ken Babcock, with co-founders John Foster and Scott Manalis, and has raised approximately $57.7 million cumulatively across multiple financing rounds from 2013 through March 2026. Headcount is reported at 11–50 employees, consistent with an early-commercialization-stage medtech company that only became revenue-eligible following its initial FDA clearance in April 2024.

Name

Affinity Biosensors

Legal name

Affinity Biosensors, LLC

Website

https://affinitybio.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

11–50 employees

Short description

Affinity Biosensors manufactures the FDA-cleared LifeScale AST system, a rapid antimicrobial susceptibility testing platform that delivers phenotypic MIC results in 4.5 hours directly from positive blood cultures, serving US hospital clinical microbiology laboratories through a capital-equipment plus consumables model.

Ownership category

akta.pro rank

Product category

Clinical Microbiology Diagnostic Instruments

NAICS

Analytical Laboratory Instrument Manufacturing (334516), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Laboratory Analytical Instruments (3826), In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Cell-Based & Potency Assays (Bioassays) (HLAGADAH)

akta.pro secondary industry

In Vitro Toxicology (Cell-based/Organ-on-chip) (HLAGAFAJ)

Keywords

• Rapid antimicrobial susceptibility testing
• Microfluidic bacterial diagnostics
• Clinical microbiology instruments
• Phenotypic AST systems
• Blood culture pathogen detection

Headquarters

HQ city

Santa Barbara

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. LifeScale AST System Hardware and Consumables: Affinity Biosensors generates revenue from the sale of its LifeScale AST benchtop instrument and associated consumables (LSGN Gram-negative kit, Yeast Kit). Consumables are stored at room temperature and contain all materials for a single assay. This follows a capital equipment + reagents business model typical of clinical diagnostics companies, where the instrument may be placed and revenue is driven by recurring consumable usage.
2. FDA-Cleared Diagnostic Kits: The company sells FDA-cleared diagnostic kits including the LSGN Gram-negative kit and the LifeScale Yeast Kit (LSYST) with Breakthrough Device Designation. These kits target specific organism groups and antifungal susceptibility testing, creating recurring revenue opportunities tied to testing volume.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Affinity Biosensors manufactures and sells the FDA-cleared LifeScale AST System, a benchtop diagnostic instrument that delivers rapid phenotypic antimicrobial susceptibility testing (AST) results directly from positive blood cultures in approximately 4.5 hours. The system uses patented microfluidic-based population profiling technology combined with an AI-Predictor to measure individual bacterial cell mass and generate accurate MIC values. Revenue is generated through sale of the LifeScale instrument together with recurring consumable kits, including the LSGN Gram-negative kit and the LifeScale Yeast Kit (LSYST).

Product overview

Affinity Biosensors offers the LifeScale platform as a unified diagnostic system for rapid antimicrobial susceptibility testing. The core LifeScale AST System provides rapid phenotypic AST results in 4.5 hours directly from positive blood cultures using patented population profiling technology. The platform is expandable through specialized kits: the LSGN Gram-negative Kit provides consumables for testing Gram-negative bacteria, while the LifeScale Yeast Kit (LSYST) extends the system to rapid antifungal susceptibility testing. All products share the same instrument platform and leverage AI-Predictor analytics for accurate MIC determination.

Differentiator

Problem solved

Functional benefit

Brands

• LifeScale: Rapid Antimicrobial Susceptibility Testing (AST) system using population profiling technology for fast and accurate phenotypic AST results directly from positive blood cultures

Products and services

• LifeScale AST System FDA-cleared rapid phenotypic antimicrobial susceptibility testing (AST) benchtop instrument for hospital clinical microbiology laboratories. Delivers AST results in approximately 4.5 hours directly from positive blood cultures using patented microfluidic population profiling technology with AI-Predictor for MIC determination. Supports up to 5 simultaneous samples with fully automated inoculation, incubation, reading, and reporting, and fits alongside standard-of-care workflows without disruption.
• LSGN Gram-negative Kit Single-assay consumable kit for the LifeScale AST System containing all materials required to perform rapid AST on Gram-negative organisms from positive blood culture. Stored at room temperature with minimal waste, intended for hospital clinical laboratories running the LifeScale platform.
• LifeScale Yeast Kit (LSYST) Antifungal susceptibility testing kit for the LifeScale AST System that enables rapid AST directly from positive blood cultures for key Candida species including C. auris, using clinically relevant antifungals such as Amphotericin B, Caspofungin, and Fluconazole. Targeted at hospital laboratories managing life-threatening fungal bloodstream infections.

Quantifiable outcome

• 4½ hours average time to result vs. 16-24 hours for conventional AST
• +5 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Direct peers

• bioMérieux: Global leader in clinical microbiology with the Vitek 2 AST system, which Affinity explicitly benchmarks against as standard of care. Both companies sell FDA-cleared phenotypic AST instruments and consumables into hospital microbiology labs.
• Beckman Coulter (Danaher): Manufacturer of the WalkAway AST system referenced in Affinity's multi-site clinical comparison. Direct competitor in hospital clinical microbiology AST with an established installed base in U.S. hospital labs.
• BD (Becton Dickinson): Sells the BD Phoenix AST system, explicitly cited in Affinity's clinical evaluation as a standard-of-care comparator. Competes in the same hospital clinical microbiology AST segment with overlapping customer base.
• Accelerate Diagnostics: Direct competitor in rapid phenotypic AST, marketing the Accelerate Pheno system for rapid identification and AST directly from positive blood cultures targeting the same hospital lab use case as LifeScale.

Emerging players

• Q-linea: Swedish developer of the ASTrIA rapid AST system for sepsis-causing pathogens. Competes in the same rapid phenotypic AST category and represents a peer emerging player pursuing faster time-to-result for bloodstream infections.
• Selux Diagnostics: Boston-based rapid AST developer targeting same-shift phenotypic antibiotic susceptibility results. Competes in the rapid AST niche with a similar value proposition around speed and antibiotic stewardship.
• Specific Diagnostics (acquired by bioMérieux): Developed a rapid phenotypic AST platform using volatile metabolomics; now part of bioMérieux. Represents an alternate rapid-AST technical approach being absorbed by the largest incumbent in the AST market.

Broad incumbents

• T2 Biosystems: Sells the T2Bacteria and T2Candida panels for rapid direct-from-blood molecular detection of sepsis pathogens. Addresses adjacent bloodstream infection diagnostics rather than phenotypic AST, but competes for the same hospital lab budget and antimicrobial stewardship mandate.
• Roche Diagnostics: Major clinical diagnostics incumbent with broad microbiology and blood-culture workflows, including blood culture media and identification systems. Competes indirectly via the broader hospital sepsis diagnostic pathway rather than rapid phenotypic AST.
• Thermo Fisher Scientific (Sensititre): Markets the Sensititre AST system alongside its broader microbiology portfolio. Competes as an incumbent AST vendor with established hospital lab relationships, though primarily in off-panel manual workflows rather than rapid blood-culture-direct AST.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/affinity-biosensors

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds10 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Affinity Biosensors